These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29043469)

  • 1. E3 ubiquitin ligases in cancer and implications for therapies.
    Wang D; Ma L; Wang B; Liu J; Wei W
    Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
    Uchida C; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting E3 ubiquitin ligases for cancer therapy.
    Sun Y
    Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBR E3 ubiquitin ligases in tumorigenesis.
    Wang P; Dai X; Jiang W; Li Y; Wei W
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):131-144. PubMed ID: 32442483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
    Liu L; Wong CC; Gong B; Yu J
    Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
    Yang L; Chen J; Huang X; Zhang E; He J; Cai Z
    Am J Med Sci; 2018 Apr; 355(4):368-376. PubMed ID: 29661351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cullin-RING Ligases as attractive anti-cancer targets.
    Zhao Y; Sun Y
    Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 ligase mechanism and regulation.
    Lechtenberg BC; Rajput A; Sanishvili R; Dobaczewska MK; Ware CF; Mace PD; Riedl SJ
    Nature; 2016 Jan; 529(7587):546-50. PubMed ID: 26789245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RBR E3 ubiquitin ligases: new structures, new insights, new questions.
    Spratt DE; Walden H; Shaw GS
    Biochem J; 2014 Mar; 458(3):421-37. PubMed ID: 24576094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3 ubiquitin ligases as cancer targets and biomarkers.
    Sun Y
    Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HECT-Type E3 Ubiquitin Ligases in Cancer.
    Bernassola F; Chillemi G; Melino G
    Trends Biochem Sci; 2019 Dec; 44(12):1057-1075. PubMed ID: 31610939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of E3 ubiquitin ligases in gastric cancer.
    Hou YC; Deng JY
    World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-substrate relationships in the ubiquitin system: approaches for identifying substrates of ubiquitin ligases.
    O'Connor HF; Huibregtse JM
    Cell Mol Life Sci; 2017 Sep; 74(18):3363-3375. PubMed ID: 28455558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the ubiquitin pathway for cancer treatment.
    Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
    Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HECT family of E3 ubiquitin ligases: multiple players in cancer development.
    Bernassola F; Karin M; Ciechanover A; Melino G
    Cancer Cell; 2008 Jul; 14(1):10-21. PubMed ID: 18598940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted modulation of E3 ligases using engineered ubiquitin variants.
    LeBlanc N; Mallette E; Zhang W
    FEBS J; 2021 Apr; 288(7):2143-2165. PubMed ID: 32867007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.